Cambridge Advisors’s Amgen AMGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $8.92M | Buy |
24,621
+141
| +0.6% | +$48.3K | 1.53% | 15 |
|
|
2026
Q1 | $8.61M | Sell |
24,480
-217
| -0.9% | -$77.4K | 1.67% | 14 |
|
|
2025
Q4 | $8.08M | Buy |
24,697
+128
| +0.5% | +$40.6K | 1.54% | 17 |
|
|
2025
Q3 | $6.93M | Buy |
24,569
+145
| +0.6% | +$42.1K | 1.35% | 19 |
|
|
2025
Q2 | $6.82M | Sell |
24,424
-63
| -0.3% | -$17.8K | 1.43% | 18 |
|
|
2025
Q1 | $7.63M | Buy |
24,487
+2
| +0% | +$591 | 1.67% | 15 |
|
|
2024
Q4 | $6.38M | Sell |
24,485
-902
| -4% | -$268K | 1.42% | 17 |
|
|
2024
Q3 | $8.18M | Buy |
25,387
+114
| +0.5% | +$37.3K | 1.79% | 14 |
|
|
2024
Q2 | $7.9M | Buy |
25,273
+55
| +0.2% | +$16.2K | 1.83% | 12 |
|
|
2024
Q1 | $7.17M | Sell |
25,218
-72
| -0.3% | -$21.1K | 1.69% | 13 |
|
|
2023
Q4 | $7.28M | Sell |
25,290
-39
| -0.2% | -$10.6K | 1.83% | 11 |
|
|
2023
Q3 | $6.81M | Buy |
25,329
+31
| +0.1% | +$7.74K | 1.83% | 10 |
|
|
2023
Q2 | $5.62M | Sell |
25,298
-147
| -0.6% | -$34.1K | 1.44% | 15 |
|
|
2023
Q1 | $6.15M | Buy |
25,445
+187
| +0.7% | +$45.9K | 1.57% | 11 |
|
|
2022
Q4 | $6.63M | Buy |
25,258
+56
| +0.2% | +$15K | 1.78% | 11 |
|
|
2022
Q3 | $5.68M | Sell |
25,202
-331
| -1% | -$80.2K | 1.63% | 11 |
|
|
2022
Q2 | $6.21M | Sell |
25,533
-54
| -0.2% | -$13.2K | 1.7% | 11 |
|
|
2022
Q1 | $6.19M | Buy |
25,587
+101
| +0.4% | +$23.2K | 1.47% | 14 |
|
|
2021
Q4 | $5.73M | Buy |
25,486
+35
| +0.1% | +$7.39K | 1.3% | 15 |
|
|
2021
Q3 | $5.41M | Buy |
25,451
+121
| +0.5% | +$27.9K | 1.32% | 15 |
|
|
2021
Q2 | $6.17M | Sell |
25,330
-32
| -0.1% | -$7.87K | 1.49% | 13 |
|
|
2021
Q1 | $6.31M | Buy |
25,362
+12
| +0% | +$2.86K | 1.61% | 12 |
|
|
2020
Q4 | $5.83M | Buy |
25,350
+102
| +0.4% | +$23.5K | 1.57% | 11 |
|
|
2020
Q3 | $6.42M | Buy |
25,248
+71
| +0.3% | +$17.6K | 1.89% | 10 |
|
|
2020
Q2 | $5.94M | Buy |
25,177
+101
| +0.4% | +$23K | 1.86% | 10 |
|
|
2020
Q1 | $5.08M | Sell |
25,076
-135
| -0.5% | -$29.5K | 1.85% | 9 |
|
|
2019
Q4 | $6.08M | Buy |
+25,211
| New | +$5.56M | 1.85% | 11 |
|
|
2019
Q3 | – | Sell |
-25,556
| Closed | -$4.71M | – | 135 |
|
|
2019
Q2 | $4.71M | Sell |
25,556
-419
| -2% | -$75K | 1.55% | 11 |
|
|
2019
Q1 | $4.93M | Sell |
25,975
-900
| -3% | -$172K | 1.68% | 10 |
|
|
2018
Q4 | $5.23M | Buy |
26,875
+96
| +0.4% | +$18.7K | 1.95% | 8 |
|
|
2018
Q3 | $5.55M | Buy |
26,779
+92
| +0.3% | +$18.1K | 1.87% | 8 |
|
|
2018
Q2 | $4.93M | Sell |
26,687
-286
| -1% | -$50.6K | 1.74% | 9 |
|
|
2018
Q1 | $4.6M | Buy |
26,973
+763
| +3% | +$140K | 1.65% | 10 |
|
|
2017
Q4 | $4.56M | Sell |
26,210
-742
| -3% | -$131K | 1.64% | 10 |
|
|
2017
Q3 | $5.03M | Buy |
26,952
+54
| +0.2% | +$9.57K | 1.93% | 9 |
|
|
2017
Q2 | $4.63M | Sell |
26,898
-324
| -1% | -$52.7K | 1.87% | 9 |
|
|
2017
Q1 | $4.47M | Sell |
27,222
-94
| -0.3% | -$15.6K | 1.84% | 8 |
|
|
2016
Q4 | $3.99M | Sell |
27,316
-239
| -0.9% | -$36K | 1.77% | 9 |
|
|
2016
Q3 | $4.6M | Buy |
27,555
+51
| +0.2% | +$8.62K | 2.03% | 7 |
|
|
2016
Q2 | $4.18M | Sell |
27,504
-247
| -0.9% | -$38.4K | 1.91% | 7 |
|
|
2016
Q1 | $4.16M | Sell |
27,751
-340
| -1% | -$50.5K | 1.93% | 7 |
|
|
2015
Q4 | $4.56M | Sell |
28,091
-58
| -0.2% | -$9.12K | 2.58% | 5 |
|
|
2015
Q3 | $3.89M | Buy |
28,149
+7,387
| +36% | +$1.16M | 2.3% | 6 |
|
|
2015
Q2 | $3.19M | Buy |
20,762
+2
| +0% | +$320 | 1.8% | 11 |
|
|
2015
Q1 | $3.32M | Sell |
20,760
-27
| -0.1% | -$4.25K | 1.93% | 10 |
|
|
2014
Q4 | $3.31M | Buy |
+20,787
| New | +$3.24M | 2.03% | 8 |
|
Other funds holding AMGN
FFM
SP
Cambridge Advisors's AMGN Position: Q2 2026 in Review
Cambridge Advisors increased its Amgen (AMGN) stake by 0.58% in Q2 2026, buying an estimated $48.3K and bringing the position to 24,621 shares worth $8.92M. The position accounts for 1.53% of the portfolio, ranked #15.
Cambridge Advisors first reported a position in AMGN in Q4 2014 and has held it in 46 quarters since. 1,262 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.
- Cambridge Advisors held 24,621 shares of Amgen worth $8.92M as of Q2 2026.
- Cambridge Advisors bought 141 Amgen shares in Q2 2026, an estimated $48.3K.
- Amgen made up 1.53% of Cambridge Advisors's portfolio in Q2 2026, its #15 holding.
- Cambridge Advisors first reported a position in Amgen in Q4 2014 and has held it in 46 quarters since.
- 1,262 funds tracked by Wall St. Rank held Amgen as of Q2 2026.
Based on Cambridge Advisors's 13F filing for Q2 2026, filed 16 Jul 2026.